Home » Stocks » VIE

Viela Bio, Inc. (VIE)

Stock Price: $34.14 USD -1.32 (-3.72%)
Updated Jan 21, 2021 1:30 PM EST - Market open
Market Cap 1.94B
Revenue (ttm) 32.32M
Net Income (ttm) -128.85M
Shares Out 54.76M
EPS (ttm) -103.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $34.14
Previous Close $35.46
Change ($) -1.32
Change (%) -3.72%
Day's Open 35.52
Day's Range 33.51 - 36.24
Day's Volume 46,024
52-Week Range 25.48 - 60.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

Viela Bio is an AstraZeneca-MedImmune spinoff. It has one approved drug and a long tailed pipeline.

Seeking Alpha - 2 months ago

Viela Bio, Inc. (VIE) CEO Bing Yao on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Company to host investor conference call and webcast today at 5:00 pm EST Company to host investor conference call and webcast today at 5:00 pm EST

GlobeNewsWire - 2 months ago

-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted ...

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoi...

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for au...

Seeking Alpha - 5 months ago

Viela Bio, Inc. (VIE) CEO Bing Yao on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for aut...

The Motley Fool - 7 months ago

Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?

Other stocks mentioned: APTO, SRPT
Seeking Alpha - 7 months ago

Viela Bio Gets Approval And Other News: The Good, Bad And Ugly Of Biopharma

Market Watch - 7 months ago

Shares of Viela Bio Inc. VIE, -0.98% were up 4.9% in premarket trading on Friday, the day after the company received approval from the Food and Drug Administration (FDA) to market Uplizna to t...

GlobeNewsWire - 7 months ago

UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive UPLIZNA™ is the first and only B cell depleter ap...

GlobeNewsWire - 7 months ago

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases...

GlobeNewsWire - 7 months ago

GAITHERSBURG, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases...

Seeking Alpha - 8 months ago

Viela Bio, Inc. (VIE) CEO Bing Yao on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Company to host investor conference call and webcast today at 5:00 pm ET Company to host investor conference call and webcast today at 5:00 pm ET

GlobeNewsWire - 8 months ago

-Safety profile comparable to placebo control-

Zacks Investment Research - 8 months ago

Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates this week.

Other stocks mentioned: GO, HCAT, LOGI, SSRM
GlobeNewsWire - 8 months ago

GAITHERSBURG, Md., April 30, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, to...

Seeking Alpha - 9 months ago

Viela Bio, Inc. (VIE) CEO Bing Yao on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Viela Bio (VIE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 10 months ago

Viela Bio (VIE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

The Motley Fool - 10 months ago

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Other stocks mentioned: APRE, FREQ, VIR
Zacks Investment Research - 10 months ago

Viela Bio (VIE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 1 year ago

GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, tod...

GlobeNewsWire - 1 year ago

GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseas...

The Motley Fool - 1 year ago

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Other stocks mentioned: APRE, FREQ
Benzinga - 1 year ago

Viela Bio (NASDAQ: VIE) made its public debut Thursday morning, opening at $21.50 after being priced at $19 per share.

Market Watch - 1 year ago

Shares of Viela Bio Inc. VIE, +4.58% rose 9% in their trading debut Thursday, before paring some of those gains, after the company sold 7.9 million shares in its initial public offering, price...

About VIE

Viela Bio, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a str... [Read more...]

Industry
Biotechnology
IPO Date
Oct 3, 2019
CEO
Dr. Zhengbin Yao
Employees
166
Stock Exchange
NASDAQ
Ticker Symbol
VIE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Viela Bio stock is "Buy." The 12-month stock price forecast is 51.67, which is an increase of 51.35% from the latest price.

Price Target
$51.67
(51.35% upside)
Analyst Consensus: Buy